Anti-6-blocked ricin (anti-B4-bR) combines the specificity of the anti-64 (CDI 9) monoclonal antibody with the protein toxin "blocked ricin." In blocked ricin, affinity ligands are attached to the ricin 6-chain to attenuate its lectin binding capacity. In a phase I trial, Anti-B4-bR was administered by 7-day continuous infusion to 1 2 patients in complete remission after autologous bone marrow transplantation (ABMT) for relapsed 6-cell nomHodgkin's lymphoma (NHL). Patients were treated at 20,40, and 50 pglkgld for 7 days. Potentially therapeutic serum levels could be sustained for 3 to 4 days. The maximum tolerated dose was 40 pglkgld for 7 days (total 280 pglkg). The dose-limiting toxicities LTHOUGH HIGH-DOSE myeloablative therapy fol-A lowed by autologous bone marrow (BM) reinfusion can induce a clinical complete remission in the vast majority of patients with relapsed B-cell non-Hodgkin's lymphoma (NHL), between 50% and 85% of these patients ultimately relapse.13' Tumor recurrence primarily is attributable to the presence of clones of lymphoma cells resistant to high-dose therapy, but reinfusion of lymphoma cells harbored within the autologous marrow probably also contributes to relap~e.~,~ In an attempt to overcome tumor cell resistance, a number of investigators have intensified the myeloablative regimen. Although complete remission rates may be increased with this approach, the morbidity and mortality of therapy also significantly We and others have also attempted to decrease the number of relapses by purging lymphoma cells from the harvested autologous Unfonmately, purging has been effective in removing residual lymphoma cells from the marrow in only 50% of patients; therefore, small numbers of residual lymphoma cells may continue to contribute to relap~e.~ In an attempt to overcome these obstacles to autologous BM transplantation (ABMT), a number of investigators have begun to treat patients after ABMT with therapies designed to overcome lymphoma cell resistance and eradicate residual neoplastic cells transferred in the reinfused BM. Because of the myelosuppressive side effects attendant to high-dose therapy, traditional chemotherapeutic agents cannot be used early after ABMT. In contrast, new agents with nonoverlapping toxicity, such as immunotoxins or cytokines, both may be delivered safely in this setting and may be capable of killing resistant residual lymphoma Over the past 3 years, we have used a novel immunotoxin to treat patients with relapsed B-cell NHL. The immunotoxin, AntLB4-blocked ricin (Anti-B4-bR) combines the B-cell specificity of the anti-B4 (CD19) monoclonal antibody (MoAb) with a toxin, termed "blocked ricin."12 In blocked ricin, which is derived from the potent protein toxin ricin, the binding of ricin is attenuated by attaching affinity ligands to the galactose binding sites that mediate nonspecific binding.I3 The resultant immunotoxin is highly cytotoxic to cells that express the CD 19 antigen and effects its cytotoxicity by inhibiting protein synthesis. j 4 Therefore, Anti-B4-bR potentially may kill lymphoma cells resistant to chemotherapy. We have evaluated this immunotoxin in two phase I trials were reversible grade IV thrombocytopenia and elevation of hepatic transaminases. Mild capillary leak syndrome was manifested by hypoalbuminemia, peripheral edema (4 patients), and dyspnea (1 patient). Anti-immunotoxin antibodies developed in 7 patients. Eleven patients remain in complete remission between 1 3 and 26 months post-ABMT (median 17 months). These results show that Anti-64-bR can be administered with tolerable, reversible toxicities to patients with 6-cell NHL in complete remission following ABMT.
A lowed by autologous bone marrow (BM) reinfusion can induce a clinical complete remission in the vast majority of patients with relapsed B-cell non-Hodgkin's lymphoma (NHL), between 50% and 85% of these patients ultimately relapse.13' Tumor recurrence primarily is attributable to the presence of clones of lymphoma cells resistant to high-dose therapy, but reinfusion of lymphoma cells harbored within the autologous marrow probably also contributes to relap~e.~,~ In an attempt to overcome tumor cell resistance, a number of investigators have intensified the myeloablative regimen. Although complete remission rates may be increased with this approach, the morbidity and mortality of therapy also significantly
We and others have also attempted to decrease the number of relapses by purging lymphoma cells from the harvested autologous Unfonmately, purging has been effective in removing residual lymphoma cells from the marrow in only 50% of patients; therefore, small numbers of residual lymphoma cells may continue to contribute to relap~e.~ In an attempt to overcome these obstacles to autologous BM transplantation (ABMT), a number of investigators have begun to treat patients after ABMT with therapies designed to overcome lymphoma cell resistance and eradicate residual neoplastic cells transferred in the reinfused BM. Because of the myelosuppressive side effects attendant to high-dose therapy, traditional chemotherapeutic agents cannot be used early after ABMT. In contrast, new agents with nonoverlapping toxicity, such as immunotoxins or cytokines, both may be delivered safely in this setting and may be capable of killing resistant residual lymphoma Over the past 3 years, we have used a novel immunotoxin to treat patients with relapsed B-cell NHL. The immunotoxin, AntLB4-blocked ricin (Anti-B4-bR) combines the B-cell specificity of the anti-B4 (CD19) monoclonal antibody (MoAb) with a toxin, termed "blocked ricin."12 In blocked ricin, which is derived from the potent protein toxin ricin, the binding of ricin is attenuated by attaching affinity ligands to the galactose binding sites that mediate nonspecific binding.I3 The resultant immunotoxin is highly cytotoxic to cells that express the CD 19 antigen and effects its cytotoxicity by inhibiting protein synthesis. j 4 Therefore, Anti-B4-bR potentially may kill lymphoma cells resistant to chemotherapy. We have evaluated this immunotoxin in two phase I trials treating patients with relapsed B-cell NHL. In the first trial, Anti-B4-bR was administered by daily bolus infusion for 5 consecutive days to 25 patients with a maximal tolerated dose (MTD) of 50 pg/kg/d (total 250 pg/kg) and the doselimiting toxicity (DLT) was defined by transient grade IV increases in hepatic transaminases and thromb~cytopenia.'~ Because additional preclinical studies suggested that higher doses of Anti-B4-bR could be administered safely by 7-day continuous infusion, we also conducted a phase I trial in a similar patient population using a 7-day continuous infusion.I6 This treatment schedule allowed potentially therapeutic serum levels to be sustained in serum for up to 4 days, and a higher MTD of 50 pg/kg/day X 7 days (total 350 pg/ kg) was achieved. In this trial, the DLT was identical to that of the bolus infusion trial although continuous infusions also led to mild, reversible capillary leak syndrome.
Although clinically significant responses, including complete remissions, were seen in both phase I trials, the majority of responses were observed in patients with lower tumor burdens. This suggested that one major obstacle to effective immunotoxin therapy might be the delivery of these agents to all of the lymphoma cells. Therefore, we hypothesized that administration of Anti-B4-bR after ABMT might lead to improved tumor cell delivery to a small number of residual tumor cells and potentially eradicate remaining resistant lymphoma cells. In this study, we report a phase I trial of Anti-B4-bR administered by 7-day continuous infusion to 12 patients with B-cell NHL in complete remission after ABMT. In the results to be reported below, we show that Anti-B4-bR can be administered in this setting with tolerable and reversible toxicity and that potentially therapeutic serum levels can be obtained consistently.
MATERIALS AND METHODS

Anti-B4-bR
Anti-B4-bR was manufactured and supplied by ImmunoGen, Inc (Cambridge, MA) as previously d e~c r i b e d . '~~'~ Anti-B4-bR was formulated as a sterile injectable solution containing 100 &mL of Anti-B4-bR dissolved in phosphate-buffered saline (PBS), pH 7.3, with I mg/mL of human serum albumin (Immuno-US, Rochester, MI) added as a carrier. Anti-B4-bR was stored at 2" to 8°C before administration. Three different lots of Anti-B4-bR were used to treat patients on this trial: P1901.003 (patients I through 4), P190K.005 (patients 5 through I I), PO191.GO4 (patient 12).
Patient Selection
Patients were eligible for this study if they had undergone ABMT for B-cell NHL at the Dana-Farber Cancer Institute (DFCI) between 6/29/90 and 8/2/9 I , the time during which the protocol was open for accrual. Tumor cells from all patients were required to show reactivity with the anti-B1 (CD20) or anti-B4 (CD19) MoAbs. Before ABMT, all patients had disease that had relapsed after one or more primary or salvage chemotherapy regimens, and all patients had chemosensitive disease as defined by the ability to achieve a minimal disease state after salvage chemotherapy. Minimal disease was defined as either a complete or partial remission, as indicated by the reduction oftumor masses to 2 cm or less, and the degree of marrow infiltration by lymphoma cells to less than 20% of the intertrabecular space. At the time of BM harvest, marrow was purged with a cocktail of three MoAbs (anti-BI, anti-B5, and J5) as previously de~cribed.'.'~ All patients received myeloablative therapy with cyclophosphamide (60 mg/kg of body weight/d), infused on each of 2 consecutive days. After completing chemotherapy, all patients received total body irradiation (TBI) in fractionated doses (200 cGy) twice daily on 3 consecutive days (total 1,200 cGy). Within 18 hours after the completion of TBI, all patients received a re-infusion of purged autologous marrow. ' Patients were eligible for treatment with Anti-B4-bR if they were in complete remission at least 60 days after re-infusion of autologous marrow. Complete remission was documented in all patients by obtaining computer tomography (CT) scans of previous sites ofdisease, gallium scans in patients with prior gallium avid disease, chest radiographs, and BM biopsies. Patients were required to have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 at the time of therapy. At protocol entry, all patients were required to have hematopoietic engraftment as defined by absolute neutrophil count r500/pL, hematocrit 2259'0, and platelet count r30,000/~L independent of transfusion. At entry, all patients were required to have a total bilirubin <2.0 mg/dL, SGOT <90 IU, SGPT < 140 IU, and creatinine <2.0 mg/dL. Patients had no prior history of hepatic veno-occlusive disease, or hepatitis B or C. In addition, patients were excluded from therapy if their serum aspartate aminotransferase (SGOT) or serum alanine aminotransferase (SGPT) increased to greater than five times the upper limit of normal at any time during ABMT. No patients had a history of lymphomatous meningitis or evidence of active infection at the time of therapy. The clinical protocol was approved by the Institutional Review Board of the DFCI, and all patients signed an informed consent form approved by that committee.
Study Design
After the documentation of complete remission, patients were admitted to the DFCI and received a continuous infusion of Anti-B4-bR via a central venous line for 7 consecutive days. Anti-B4-bR was administered at doses of 20,40, and 50 pg/kg/d for 7 days. The study was designed to gradually escalate the dose of Anti-B4-bR until grade 111 National Cancer Institute Common Toxicity Criteria toxicity was reached. For the purpose of this protocol, dose escalation was continued until grade IV elevation of hepatic transaminases were seen. In addition, grade I11 or IV myelosuppression of less than 7 days duration was not considered a dose-limiting toxicity. The dose-limiting toxicity was defined as that toxicity that resulted in a cessation of dose escalation. At least three patients underwent therapy at each dose until the dose-limiting toxicity was reached. If the dose-limiting toxicity was not reached at a given dose level for all three patients, the next three patients were treated at the next dose level.
Patients were eligible for retreatment at the same dose every 28 days if they continued to meet protocol eligibility requirements, had recovered from all toxicities ofgrade 2 or greater incurred by the first course of therapy, did not develop grade 4 toxicity with the first c o m e of therapy, failed to develop human anti-mouse antibody (HAMA) or human antincin antibody (HARA) after their initial course, and agreed to continue on the protocol.
Blood was drawn daily from each patient and samples were obtained for pharmacologic analysis. Weekly blood samples were obtained for HAMA/HARA determination. Follow-up laboratory studies were obtained weekly for 4 weeks after therapy. Formal restaging of all patients including CT scans, gallium scans in patients with prior evidence of gallium-avid disease, and BM biopsies has been completed at 6-month intervals post-ABMT. Follow-up data on all patients obtained through 8/3 1/92 are included in this report.
Pharmacology
Blood samples were obtained for the determination of serum levels of Anti-B4-bR just before immunotoxin infusion and daily during immunotoxin infusion. Anti-B4-bR concentration in serum was determined by using two independent enzyme-linked immunosorbent assay (ELISA) methods. The two ELISAs were sandwich assays in which the Anti-B4-bR conjugate was captured on plates coated with sheep anti-mouse IgG (Fc specific) and then assayed with either goat anti-mouse IgG immunoglobulin conjugated to alkaline phosphatase or rabbit antiricin Ig followed by goat anti-rabbit Ig conjugated to alkaline phosphatase. A signal amplification method (Bethesda Research Laboratories) was used, allowing the use of highly diluted serum samples and reducing the nonspecific background signals.
HAhiA/HARA Detection
HAMA and HARA were measured by established ELISA techniques that take advantage of the multivalency of the Ig molecules. The antigens anti-B4 or blocked ricin were coated on plates to capture the specific human antiserum. Biotinylated antigen was then captured by the bound human antiserum and assayed with streptavidin conjugated to horseradish peroxidase. In both assays, the antigens were used in excess and the final signals recorded were directly proportional to the amount of absorbed specific human antibody. HAMA and HARA were considered positive if the patient's value was greater than two standard deviations above the value for a negative control.
Polymerase Chain Reaction (PCR) Amplification
Nested oligonucleotide amplification of genomic DNA was performed as previously described at both the major breakpoint and the minor cluster region of the bc/-2/IgH hybrid gene in BM samples obtained from patients before BM harvest, at BM harvest, postmarrow purging with MoAbs and complement, before therapy with Anti-B4- bR, and posttherapy with Anti-B4-bR.4~'*~'g Standard precautions were taken against cross-contamination of amplified material. For each amplification, DNA from a dilution of the human lymphoma B-cell line DHL-6 (which contains a bcl-2 translocation) in BM cells served as a weak positive control. DHL-6 was a gift from Dr A. Epstein (University of Southern California, Los Angeles). PCR buffer containing no DNA served as a negative control. Each sample was analyzed at least three times at each breakpoint site. In addition, in samples without detectable PCR product, PCR amplification was repeated with oligonucleotide primers specific to the gene encoding the human B-cell activation antigen B7, to ensure that DNA could be amplified in all samples.
RESULTS
Patient Selection and Characteristics
Between 6/29/90 and 81219 1 , 2 1 patients with B-cell NHL in sensitive relapse attained a minimal disease state and underwent anti-B-cell MoAb-purged ABMT. Of these 21 patients, 16 were eligible to receive post-ABMT therapy with Anti-B4-bR, and I2 were treated. Reasons for ineligibility included early relapse (n = l), inadequate platelet engraftment (n = 2), cyclophosphamide bladder toxicity (n = l), and elevated liver function tests (n = l). Eligible patients were not treated because of patient refusal (n = 3) and patient not offered therapy by physician (n = 1).
As indicated in Table I , 12 patients received Anti-B4-bR between 61 and 208 days after ABMT (median 83 days). Although we intended to treat patients at the earliest time they met all eligibility criteria post-ABMT, three patients were treated more than 104 days post-ABMT. The first two patients, treated at day 151 and 140, respectively, both were eligible to receive Anti-B4-bR by day 90 post-ABMT. Unfortunately, production of Anti-B4-bR was delayed during this time period, and there was no immunotoxin available for clinical use until the time of actual treatment. Patient 1 1 was not treated until 208 days post-ABMT. This patient had delayed platelet engraftment, and therefore was not eligible for therapy until day I 10. At that time, the patient's physician was concerned about possible disease recurrence and elected to wait 3 months before repeat restaging, confirming a complete remission, and refemng the patient for protocol therapy at day 208. Table 1 summarizes the pretransplant and posttransplant characteristics ofthe patients. Eight males and 4 females with a median age of 47 (range 3 1 to 54) were treated. Ten of 12 patients had low-grade NHL at the time of ABMT, and 2 patients had intermediate grade NHL. All 12 patients received extensive prior treatment with 75% receiving 3 or more chemotherapeutic regimens before high-dose myeloablative therapy. All patients had a history of nodal infiltration, 7 had BM involvement, and only 2 had extranodal disease. Although all patients had achieved a minimal disease state at the time of harvest, none had achieved a complete clinical remission. At the time of BM harvest, all 12 patients still had minimal nodal infiltration and 7 had minimal histologic BM infiltration representing less than 5% of the intertrabecular space. In addition, 9 of these patients showed a bcl-2 translocation in their original tumor biopsies and BM samples. At the time of BM harvest, all 9 patients had residual lymphoma cells in their marrow detected by PCR for the bcl-2 translocation.
Dose Escalation and Pharmacology
Patients were treated in cohorts of three and the dose of Anti-B4-bR was escalated with each successive cohort until the MTD was achieved and the DLT was defined. As seen in Table I , 3 patients successfully received Anti-B4-bR at 20 pg/kg/d X 7 days, followed by 3 patients treated with 40 pg/kg/d X 7 days. Because grade III/IV toxicity was reached in the 2 patients at the 50 pg/kg/d dose level (toxicity described below), the dose was again decreased to 40 pg/kg/d and an additional four patients were treated to refine estimates of clinical toxicity. All patients completed the full 7 days of treatment except one patient at 40 pg/kg/d (patient 9), who developed grade IV thrombocytopenia and hepatotoxicity after 5 days of therapy, and one at 50 pg/kg/d (patient 7), who developed grade IV thrombocytopenia after 6 days of therapy. Ten patients received only one course of Anti-B4-bR and 2 patients were retreated at the same dose level as their initial therapy. Patients were not retreated for the fol- lowing reasons: Grade IV thrombocytopenia or hepatotoxicity during the initial course (n = 4), pneumonitis 3 weeks following the initial course (n = I), posttherapy macular hemorrhage (n = l), HAMA/HARA development before the second course of therapy (n = 3), and refused a second course of therapy (n = 1).
Serum levels of immunoconjugate were determined by ELISA in all patients by separate detection of the blocked ricin and anti-B4 moieties of the conjugate. There was a highly reproducible relationship between the dose of Anti-BCbR administered by continuous infusion and the serum level. As seen in Fig 1 and Table 2 
Toxicity
Anti-B4-bR administration resulted in systemic toxicities of grade I and I1 occumng in nearly all patients (Table 3) . Nine patients developed fevers in association with therapy, with five patients developing fevers above 100.5"F. These fevers usually began within 24 to 48 hours of initiation of therapy, and resolved within 24 hours of the conclusion of therapy. Tolerable and self-limited nausea and vomiting were observed in five patients. At 20 pg/kg/d fatigue was absent, and myalgias occurred in only a single patient. Fatigue and myalgias were seen in most patients treated at 40 and 50 pg/kg/d. Although they did not define the MTD or DLT, myalgias reached grade I11 toxicity and persisted for 4 to 8 weeks after the completion of treatment. Nevertheless, creatine phosphokinase (CPK) elevations were not observed and no patient manifested rhabdomyolysis. Likewise, many patients had profound fatigue, and four patients had a decline in their ECOG performance status to 3. There were no allergic manifestations of immunotoxin administration, including anaphylaxis, rash, or immune complex formation. Patients showed no evidence of cardiac toxicity on serial electrocardiograms. Further, there was no nephrotoxicity, proteinuria,
Overall toxicity.
For or change in creatinine immediately after therapy. Five patients treated at doses of 40 and 50 pg/kg/d developed headaches without evidence of other neurologic toxicity. Toxicity was not dependent on the duration of time that had elapsed between ABMT and Anti-B4-bR therapy. The major toxicity seen in this trial, which proved dose-limiting and defined the MTD, was grade 1V thrombocytopenia. In 1 1 of the 12 patients, the platelet count declined during the course of therapy, with a decrease in platelets noted within 24 to 48 hours after instituting therapy. As seen in Table 4 , the platelet count at the inception of treatment widely ranged from patient to patient. Four patients developed grade IV thrombocytopenia during the course of therapy with platelet counts decreasing to less than 25,000/ pL. However, two of these patients began therapy with grade I11 thrombocytopenia, with platelet counts of 50,00O/pL and 32,00O/pL, respectively. Platelet counts returned to baseline within 22 days of completing therapy in all patients for whom follow-up data are available. Two patients had minor bleeding episodes during the course of therapy, which were not associated with grade IV thrombocytopenia. Patient 1 developed mild hemorrhoidal bleeding on day 7 of therapy, and received a platelet transfusion despite a nadir platelet count of 36,000/ pL. Patient 12 developed a macular hemorrhage 1 week after completing therapy, and received a platelet transfusion at that time. This lesion resolved without a residual visual deficit. In no patient was thrombocytopenia associated with an elevated prothrombin time (PT) or partial thromboplastin time (PTT).
Leukopenia was not apparent in any patient, but leukocytosis occurred in two patients with white blood cell (WBC) counts increasing to above lO,OOO/pL in the absence of infection (Table 3) . Anemia is more difficult to assess in this patient population, because it is a common finding in the early post-ABMT period even in the absence of therapy with Anti-B4-bR. Moreover, patients underwent phlebotomy of up to 250 mL during the week of therapy for the required laboratory studies. However, five patients did show a decline
Hematologic.
in their hemoglobin of one grade from baseline during the course of therapy.
Two patients developed hemolytic-uremic syndrome 60 to 90 days after completing therapy with Anti-B4-bR.20 Patient 5 was noted to have anemia (hemoglobin [Hgb] 8.3 g/ dL), thrombocytopenia (platelets 63,OOO/pL), and a creatinine of 2.1 mg/dL. These abnormalities resolved spontaneously over the next 2 months. Patient 10 also developed hemolyticuremic syndrome, in this case 90 days after Anti-B4-bR therapy. Again, this was characterized by self-limited thrombocytopenia, anemia, and renal dysfunction.
Transient elevations of SGOT and SGPT also occurred and contributed to the definition of the MTD. As seen in Table 3 , grade 111 transient elevations of SGOT and SGPT occurred in eight patients and grade IV elevations of SGOT and SGPT occurred in one patient. The increase in transaminase elevations began within 24 to 48 hours of initiating therapy, achieved a peak at the conclusion of therapy, and resolved within 22 days (Table 4) . Table 4 displays the elevation of hepatic transaminases seen at each dose. This is reflected as the ratio of the peak SGOT and SGPT divided by the upper limit of normal value for those parameters. Although hepatic transaminases were elevated in most patients on this trial, other parameters of hepatic function, including prothrombin time, partial thromboplastin time, alkaline phosphatase, and bilirubin, remained unchanged. In prolonged follow-up, no patients have developed evidence of sustained or recurrent hepatic abnormalities.
All patients on this trial developed reductions in serum albumin during the course of the infusion, with six patients developing a decrease of 20% or more from baseline (Table 3) . Hypoalbuminemia was accompanied by peripheral edema in four patients and dyspnea in one patient. The peripheral edema lasted over 1 year posttherapy in a single patient, and resolved within 2 to 3 months after therapy in the remainder of the patients. Dyspnea was not accompanied by abnormalities on physical examination or radiographic studies, but was as-
Hepatotoxicity.
Hypoalbuminemia and capillary leak syndrome.
For personal use only. on August 30, 2017. by guest www.bloodjournal.org From In 10 of the 12 patients, levels of serum Ig were determined before and after therapy with Anti-B4-bR. All 10 patients began therapy with low or low-normal levels of serum IgG, and 9 experienced a decrease in IgG levels during therapy ranging from 8% to 41% (median decrease 24%). Further follow-up data were not obtained until approximately 6 months posttherapy, at which time levels had returned to baseline. It is unlikely that such a rapid decline in IgG levels represents a decrease in Ig synthesis, but rather more likely HAMA/HARA. reflects a manifestation of capillary leak syndrome with an associated decrease in intravascular protein concentration.
Although Ig levels were decreased transiently, there was no apparent increase in infectious complications in patients receiving AntLB4-bR. Patient 10 developed pneumonitis within I month after Anti-B4-bR therapy, but work-up including bronchoscopy failed to show a definite infectious etiology. Nevertheless, the patient received antibiotic therapy and his pulmonary infiltrate resolved. No other patients developed infectious complications in the first 90 days after Anti-B4-bR therapy.
Two patients received a second course of therapy with Anti-B4-bR. Both patients developed HAMA and HARA early during the second course of therapy, and neither patient had detectable serum levels of Anti-B4-bR, consistent with rapid clearance of the immunotoxin. In no patient on this study, including the two who developed antibodies during the second course of therapy, was there any evidence of allergic manifestations of HAMA/HARA. No patients showed evidence of immune complex formation.
Clinical Responses
Because all patients were in complete remission at the outset of therapy, clinical responses are impossible to assess on this phase I study. Of note, 1 I of the I2 patients remain in clinical complete remission between 13 and 26 months after ABMT (median 17 months). 
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It may be possible to assess responses on a molecular level by performing PCR analysis to examine for the presence of residual lymphoma cells that possess the bcl-2 translocation. Before BM transplant, tumor samples obtained from 9 of the 12 patients were identified as containing a PCR amplifiable translocation (Table 6) . Unfortunately, data are not available to assess the efficacy of marrow purging with MoAbs and complement in all of these patients, but at least two patients had detectable residual lymphoma cells in the reinfused marrow. After ABMT, all patients had BM biopsies that were histologically negative for residual lymphoma. However, four of these patients had residual cells with the bcl-2 translocation detected by PCR analysis. Post Anti-B4-bR therapy BM biopsies in three of these patients show no evidence of cells with the bcl-2 translocation, and all patients remain in clinical complete remission. By contrast, patient 7, who had no PCR detectable lymphoma cells at the time of Anti-B4-bR therapy, did have evidence of lymphoma cells by PCR posttherapy, and ultimately had a relapse of disease 13 months post-ABMT. Patient 6 had evidence of lymphoma cells in the bone marrow both before and after Anti-B4-bR therapy, but continues to remain in a clinical complete remission.
DISCUSSION
Despite the high rates of complete remission attained early after ABMT for B-NHL, the majority of patients undergoing high-dose therapy ultimately relapse. In an effort to enhance the durability of these complete remissions, investigators have attempted to provide additional therapy to patients post-ABMT. We have reported previously that Anti-B4-bR shows in vitro and in vivo cytotoxicity against B-cell neoplasms, and therefore may be considered as an agent to use in posttransplant therapy. Although we have shown that Anti-B4-bR can be administered safely to patients with relapsed B-NHL, we undertook the present trial to determine whether Anti-B4-bR can be administered safely to patients early after ABMT, to determine the toxicity profile in this setting, and to determine the MTD.
In the present report, we show that Anti-B4-bR can be administered by continuous infusion for 7 days to patients in complete remission after ABMT for relapsed B-cell NHL. The MTD was 40 pg/kg/d (total dose 280 pg/kg) with grade IV reversible thrombocytopenia and transient elevations of hepatic transaminases defining the DLT. In addition, systemic side effects including fever, fatigue, and myalgias occurred frequently in these patients. Mild reversible capillary leak syndrome manifested by hypoalbuminemia and edema was observed at all dose levels, but did not limit dose escalation. A plateau serum level of Anti-B4-bR was achieved within 3 to 4 days after beginning the infusion in all patients, and that level could be sustained for the duration of the infusion. In patients receiving doses of 40 pg/kg/d or above, serum levels above 1.0 nmol/L could be achieved within 72 hours. In vitro cytotoxicity studies show that 3 logs of a malignant Bcell line can be depleted after 24 hour exposure to Anti-B4-bR at equivalent concentration^.'^ The levels achieved in the serum of these patients therefore potentially were therapeutic. Eleven of the 12 patients treated remain in continuous complete remission from 13 to 26 months post-ABMT (median 
months)
. Thus, this study shows that continuous infusion of anti-B4-bR at 40 pg/kg/d for 7 days results in the attainment of potentially therapeutic serum levels of immunotoxin post-ABMT with transient, tolerable toxicities.
Previous clinical trials using immunotoxins for the therapy of both hematologic malignancies and solid tumors have been conducted in patients with relapsed, bulky t~m o r s .~l -~' Although clinical responses have been observed, most were partial and transient. One explanation for the limited efficacy observed for these highly cytotoxic agents is inadequate delivery to the neoplastic cell surface. Immunotoxins are large molecules and their diffusion into sizable tumor masses is likely to be hampered.28 Moreover, immunotoxins can bind to normal and neoplastic cells bearing the target antigen that circulate in the blood stream, leading to rapid clearance of the i m m~n o t o x i n .~~ This trial was designed to circumvent these obstacles by administering Anti-B4-bR to patients with minimal tumor burdens. Early post-ABMT, these patients have low levels of circulating normal and neoplastic B-lymphocytes that can bind Anti-B4-bR.30 Because all patients were in clinical complete remission at the time of therapy, the delivery of Anti-B4-bR to the surface of residual malignant cells should be optimal. This study could not address directly whether immunotoxin was bound to the lymphoma cell surface because the number of residual lymphoma cells post-ABMT are below our present levels of detection. However, the consistent time interval required to achieve steadystate levels of immunotoxin at each dose level as well as the relatively consistent level of immunotoxin observed at each dose escalation provide evidence that therapeutic levels of immunotoxin were available to bind to residual lymphoma cells. These data contrast with those of our previous studies where circulating tumor cells led to the achievement of variable serum levels, reflecting the accessibility of the tumor to Anti-B4-bR.'',I6 The lower MTD of 280 pg/kg observed in this trial (as contrasted with the MTD of 350 pg/kg when Anti-B4-bR was administered by 7-day continuous infusion to patients with bulky relapsed lymphomas) also supports the notion of increased availability of Anti-B4-bR for uptake by both normal and malignant cells. Together, these results suggest that delivering immunotoxin to patients in complete remission after ABMT increases the likelihood that theraFor personal use only. on August 30, 2017. by guest www.bloodjournal.org From peutic levels of immunotoxin will be delivered to the surface of remaining tumor cells.
A major concern of this study was whether patients could tolerate additional cytotoxic treatment within the first 6 months after ABMT. Although these patients recently had received high-dose chemotherapy and total body irradiation, and were still recovering from transplant related toxicities, the side effect profile of Anti-B4-bR in the posttransplant setting was similar to that seen in patients with relapsed bulky NHL who also received continuous infusion of this drug.I6 In the present trial, the MTD was defined by grade IV thrombocytopenia occurring in 4 of 12 patients. The fact that thrombocytopenia was the dose-limiting toxicity reflects the lower baseline platelet counts in patients treated post-ABMT compared with those of patients on our earlier studies. With the possible exception of a patient who developed a macular hemorrhage, no patient had bleeding secondary to the thrombocytopenia, and reductions in platelets resolved rapidly in nearly all patients. Other toxicities were comparable with those observed in the previous trial using continuous infusion Anti-B4-bR. Most importantly, these included transient hepatic transaminase elevations, nausea and vomiting, fever, fatigue, and myalgias. Although the MTD of Anti-B4-bR was lower on this trial, the serum level required to induce each toxicity was comparable. This again reflects the higher serum level that can be achieved at any given administered state in the absence of significant numbers of normal and neoplastic B cells. Importantly, no new toxicities were observed on this trial, and the anticipated toxicities were not magnified in patients treated early post-ABMT. This was especially true for capillary leak syndrome, which was clinically significant in only 5 patients, with persistent peripheral edema in 4 patients and shortness of breath in I patient. Hemolyticuremic syndrome (HUS) was observed in two patients on this trial, but this side effect has been reported in 10% of patients undergoing ABMT at our center.20 The small number of patients treated on this trial render it impossible to determine whether the incidence of HUS is increased after treatment with Anti-B4-bR. Considering the small number of patients treated in this trial, we cannot resolve the question of whether toxicity was more pronounced and prolonged in patients treated closer to the time of high-dose myeloablative therapy. In future studies, we will attempt to treat all patients within the first 120 days post-ABMT. Theoretically, it might be advantageous to treat patients within 30 to 60 days post-ABMT, but post-ABMT thrombocytopenia and abnormalities of liver function tests will likely make this approach less feasible.
Another purpose of conducting this study in patients post-ABMT was to treat patients at a time when they were immunosuppressed in order to reduce the frequency of HAMA and HARA formation and possibly administer more courses of Anti-B4-bR. Both the murine MoAb and the protein toxin are immunogenic when administered to patients. Nearly all solid-tumor patients who receive immunotoxins develop HAMA and HARA, and up to 71% of leukemia and lymphoma patients likewise may develop an immune res p o n~e .~'~~~.~~ Our prior studies showed that patients do not recover normal numbers of circulating B cells for 3 to 6 months after ABMT, and that their B cell and T cell functions are significantly suppressed in vitro for the first year after ABMT.30 Despite this degree of immunosuppression, 7 of the 12 patients treated developed HAMA and/or HARA. However, there was a trend toward reduced HAMA and HARA development with higher doses of Anti-B4-bR. These data suggest that higher doses of Anti-B4-bR may deplete normal B cells capable of responding to the immunotoxin, but the extent of decrease in B cell numbers and function will need to be examined in future studies. Only two patients received a second course of therapy, and both patients developed HAMA and HARA during the second course. Therefore, if multiple cycles prove to be necessary to achieve prolonged disease-free remissions, a different treatment schedule or additional immunosuppression may be necessary to deliver multiple courses. Because most patients at the MTD did not produce anti-immunotoxin antibody until 4 weeks posttreatment, one approach might be to treat patients every 14 days rather than every 28 days. In an ongoing pilot study, we have been able to administer Anti-B4-bR at 14-day intervals at a dose of 30 pg/kg/d without significant toxicity.
The ultimate objective of this study was to administer adjuvant therapy in an effort to prevent relapses after ABMT. Because most patients achieve clinical complete remission early after ABMT, occult residual lymphoma cells either in the reinfused marrow or in the patient must contribute to relapse. Anti-B4-bR, which exerts its cytotoxicity through the inhibition of protein synthesis, may provide a non-crossresistant therapy with which to treat these patients. The small number of patients treated on this trial and the short followup permit no definitive conclusions to be made regarding the efficacy of this therapy. To date, only one patient on this trial has relapsed, with follow-up ranging from 13 to 26 months post-ABMT. Of note, all patients on this trial were in partial remission at the time of ABMT. However, it is conceivable that many of the patients on this trial were at low risk of early relapse because they had low-grade NHL, were in complete remission 5 to 8 months post-ABMT, and lacked detectable bcl-2 positive cells at the time of therapy. Considering the small number and heterogeneity of the patients treated on this trial, it is not possible to determine whether Anti-B4-bR adjuvant therapy has contributed to the disease-free survival. The possibility that Anti-B4-bR contributed to the eradication of residual bcl-2 positive cells in 3 patients on this study is intriguing, but will require validation in future studies designed to address this issue directly.
